Sciwind has two Western partners for its obesity drug, but is open to more

Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet.

Raccontata daendpoints.news